GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » United Health Products Inc (OTCPK:UEEC) » Definitions » Debt-to-EBITDA

United Health Products (United Health Products) Debt-to-EBITDA : -0.46 (As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is United Health Products Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

United Health Products's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.74 Mil. United Health Products's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.04 Mil. United Health Products's annualized EBITDA for the quarter that ended in Mar. 2024 was $-1.70 Mil. United Health Products's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was -0.46.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for United Health Products's Debt-to-EBITDA or its related term are showing as below:

UEEC' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.63   Med: -0.21   Max: -0.01
Current: -0.43

During the past 13 years, the highest Debt-to-EBITDA Ratio of United Health Products was -0.01. The lowest was -0.63. And the median was -0.21.

UEEC's Debt-to-EBITDA is ranked worse than
100% of 435 companies
in the Medical Devices & Instruments industry
Industry Median: 1.19 vs UEEC: -0.43

United Health Products Debt-to-EBITDA Historical Data

The historical data trend for United Health Products's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

United Health Products Debt-to-EBITDA Chart

United Health Products Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.06 -0.04 -0.01 -0.43 -0.31

United Health Products Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.16 -0.40 -0.44 -0.44 -0.46

Competitive Comparison of United Health Products's Debt-to-EBITDA

For the Medical Instruments & Supplies subindustry, United Health Products's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


United Health Products's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, United Health Products's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where United Health Products's Debt-to-EBITDA falls into.



United Health Products Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

United Health Products's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.736 + 0.048) / -2.502
=-0.31

United Health Products's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.738 + 0.04) / -1.696
=-0.46

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.


United Health Products  (OTCPK:UEEC) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


United Health Products Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of United Health Products's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


United Health Products (United Health Products) Business Description

Traded in Other Exchanges
N/A
Address
526 Commerce Circle, Suite No. 120, Mesquite, NV, USA, 89027
United Health Products Inc is a US-based company. It mainly manufactures and markets a patented hemostatic gauze for the healthcare and wound care sectors. The company's product HemoStyp is derived from regenerated oxidized cellulose, which is naturally designed to absorb exudate from superficial wounds and helps control bleeding. It markets its product to dental and medical markets as well as, sports, military and veterinary sectors, and others. The company's trademarks include Boo Boo Strips; The Ultimate Bandage; Hemostrips; CelluSTAT and Nik Fix.
Executives
Brian David Thom officer: CEO 10624 S EASTERN AVE., STE A209, HENDERSON NV 89052
Kristofer Heaton officer: Vice-President Finance, CFO 526 COMMERCE CIRCLE, STE 120, MESQUITE NV 89027
Nate Knight director C/O MORSE & MORSE, PLLC, 1400 OLD COUNTRY ROAD, SUITE 302, WESTBURY NY 11590
Louis Schiliro officer: Chief Operating Officer 10624 S. EASTERN AVENUE, STE. A209, HENDERSON NV 89052
Douglas K Beplate officer: CEO
Robert J. Denser director 10624 S. EASTERN AVE., STE. A209, HENDERSON NV 89052
John Vito Capotorto director 1090 KING GEORGES POST ROAD, SUITE 501, EDISON NJ 08837
Sherman Lazrus director
Rodney Paul Leibowitz director 420 EAST 54TH STREET, APARTMENT 15B, NEW YORK NY 10022
Michael R. Wiechnik director 11 PRESWICK DR., MEDFORD NJ 08055
Richard Rifenburgh director 2637 E. ATLANTIC BLVD., #133, POMPANO BEACH FL 33062
Phillip David Forman director, officer: President, Chairman and CEO 1090 KING GEORGES POST RD,501, EDISON NJ 08837
Jan E Chason director, officer: Chief Financial Officer 120 WALL STREET, SUITE 2401, NEW YORK NY 10005
Kelly Thomas Hickel director, officer: Chief Executive Officer 1630A 30TH STREET, SUITE 300, BOULDER CO 80301
Patrick Donelan 10 percent owner 3570 LAKEVIEW DRIVE, DELRAY BEACH FL 33445